Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | EDNRA | P25101 | 2/20 | 0.42 |
| ▸ | EDNRB | P24530 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15251730 | 0.89 | ALDH1A1 (0.45) | ALDH1A1MEN1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL15251743 | 0.89 | MDM2 (0.53) | ALDH1A1KDM4ESMN1; SMN2EDNRAEDNRB | |
| SCHEMBL15251881 | 0.85 | FFAR1 (0.55) | ALDH1A1SMN1; SMN2EDNRAEDNRBFFAR1 | |
| SCHEMBL15251820 | 0.85 | FFAR1 (0.54) | ALDH1A1KDM4EMEN1GAAKMT2A | |
| SCHEMBL15251874 | 0.84 | POLB (0.42) | ALDH1A1KDM4EMEN1GAAKMT2A | |
| SCHEMBL15256137 | 0.83 | ALDH1A1 (0.49) | ALDH1A1KDM4EMEN1GAAKMT2A | |
| SCHEMBL15252107 | 0.82 | HTT (0.44) | ALDH1A1KDM4EGAASMN1; SMN2EDNRA | |
| SCHEMBL15251882 | 0.82 | EDNRB (0.47) | ALDH1A1KDM4EMEN1GAAKMT2A | |
| SCHEMBL15255045 | 0.80 | KDM4E (0.43) | ALDH1A1KDM4ESMN1; SMN2HTT | |
| SCHEMBL15252106 | 0.80 | ALDH1A1 (0.47) | ALDH1A1KDM4EMEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2639212-B1 | Enantioselective organic anhydride reactions | PROVOST FELLOWS & SCHOLARS COLLEGE OF THE HOLY UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2016-03-09 | — | — | EP | disclosed |
| US-9050586-B2 | Enantioselective organic anhydride reactions | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2015-06-09 | — | — | US | disclosed |
| US-20130245268-A1 | ENANTIOSELECTIVE ORGANIC ANHYDRIDE REACTIONS | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD (IE) | 2013-09-19 | — | — | US | disclosed |
| EP-2639212-A1 | Enantioselective organic anhydride reactions | The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin (IE) | 2013-09-18 | — | — | EP | disclosed |
| US-20050043411-A1 | Process for preparing homophthalate derivatives | TJGEL, LLC | 2005-02-24 | — | — | US | disclosed |
| US-6797838-B2 | Process for preparing homophthalate derivatives | ILEX PRODUCTS, INC. | 2004-09-28 | — | — | US | disclosed |
| EP-1404662-A2 | PROCESS FOR PREPARING ISOCOUMARINS | Ilex Products, Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20040024240-A1 | Process for preparing homophthalate derivatives | GENZYME CORPORATION | 2004-02-05 | — | — | US | disclosed |
| US-6664401-B2 | Reacting a isochroman-1,3-dione with a carbonyl compound whose carbonyl group is substituted with an acyl activating group, in the presence of a base and a solvent; use making anticancer agents for example | ILEX PRODUCTS, INC. | 2003-12-16 | — | — | US | disclosed |
| US-20030105340-A1 | Process for preparing isocoumarins | GENZYME CORPORATION | 2003-06-05 | — | — | US | disclosed |
| WO-2003004486-A2 | PROCESS FOR PREPARING ISOCOUMARINS | ILEX PRODUCTS, INC. (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245268-A1 | ENANTIOSELECTIVE ORGANIC ANHYDRIDE REACTIONS | AKR1B10, ALDH3A1, AKR1C4 | ALDH1A1 34/4885KDM4E 2106/4885MEN1 910/4885 |
| US-20030105340-A1 | Process for preparing isocoumarins | DHPS, IDH2, IDH1 | ALDH1A1 1178/4885KDM4E 1498/4885MEN1 847/4885 |
| US-20050043411-A1 | Process for preparing homophthalate derivatives | HPD, HAAO, PAH | ALDH1A1 669/4885KDM4E 1794/4885MEN1 522/4885 |
| US-20040024240-A1 | Process for preparing homophthalate derivatives | HPD, HAAO, PAH | ALDH1A1 669/4885KDM4E 1794/4885MEN1 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.